Do we need oxytocin to treat schizophrenia? A randomized clinical trial
Section snippets
Background
Schizophrenia is a complex mental disorder and an important public health problem. Although both First Generation Antipsychotics (FGAs) and Second Generation Antipsychotics (SGAs) are effective in treating schizophrenia, many patients remain partial- or non-responders, as shown by over fifty years of follow-up studies (Hegarty et al., 1994). In particular, the negative symptom triad, namely social cognitive impairment, low motivation and blunted motivational affect, is particularly resistant to
Participants
Subjects with a DSM-IV diagnosis of schizophrenia for at least one year, confirmed by Structured Clinical Interview (SCID) for DSM-IV interview, were enrolled. Main inclusion criteria were: age range 18–45 years and short-medium duration of illness (< 11 years).
Other main inclusion criteria included: PANSS score of at least 55 and a Clinical Global Impressions—Severity (CGI-S) scale score of at least 4 (moderately ill) at randomization, with a trustworthy caregiver ensuring necessary support
Results
Overall, 32 subjects were included in the trial (16 patients for each group). One patient discontinued pharmacological treatment (usual and experimental) in the first period of the intervention and subsequently, at month 3, dropped out of the study (Fig. 1). Follow-up evaluations ended in April 2015, when the last patient completed the treatment period.
Table 1 shows the sample's main socio-demographic and clinical characteristics. Eighty one per cent of completers were male, with a mean age of
Discussion
Several meta-analyses and follow-up studies have shown that a substantial proportion of patients with schizophrenia do not respond at all, or show only a partial response to anti-psychotic (AP) treatment, in particular as far as negative symptoms are concerned (Fusar-Poli et al., 2015, Leucht et al., 2012). This situation has prompted researchers and clinicians to study possible additions to AP treatment in order to improve response rates for remissions and, if possible, recovery for a larger
Conflict of interest
All authors report no biomedical financial interests or potential conflicts of interest. This work was entirely supported by the Italian Ministry of Health (Ministero della Salute) grant RF2010-2311148.
Role of the funding source
The funding body (Italian Ministry of Health) funded the project in the framework of the annual call of applications for biomedical research. The funding source had no role in the design and in the conduct of the study, in data analyses, in the interpretation of results and in the writing of the study report.
Acknowledgements
This work was supported by the Italian Ministry of Health (Ministero della Salute) grant RF2010-2311148. Many thanks are due to Dr. Vincenzo Giordano (SIGMA-TAU) for his invaluable support in all stages of the project, who kindly provided the study drugs on a complimentary basis.
This paper is dedicated to the memory of Michele Tansella, who emphasized the importance of rigorous evaluation of any treatment methods in psychiatry during all his career.
References (36)
- et al.
Effects of single dose intranasal oxytocin on social cognition in schizophrenia
Schizophr. Res.
(2013) - et al.
Intranasal oxytocin increases positive communication and reduces cortisol levels during couple conflict
Biol. Psychiatry
(2009) - et al.
Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients
Biol. Psychiatry
(2010) - et al.
Improving social perception in schizophrenia: the role of oxytocin
Schizophr. Res.
(2013) - et al.
Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits
Schizophr. Res.
(2008) - et al.
Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study
Schizophr. Res.
(2013) - et al.
Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis
Lancet
(2012) - et al.
Oxytocin and social cognition in affective and psychotic disorders
Eur. Neuropsychopharmacol.
(2015) - et al.
Intranasal oxytocin reduces psychotic symptoms and improves theory of mind and social perception in schizophrenia
Schizophr. Res.
(2011) - et al.
Sniffing around oxytocin: review and meta-analyses of trials in healthy and clinical groups with implications for pharmacotherapy
Transl. Psychiatry
(2013)